IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v26y2025i3d10.1007_s10198-024-01711-0.html
   My bibliography  Save this article

Trends in NICE technology appraisals of non-small cell lung cancer drugs over the last decade

Author

Listed:
  • Lotte Westerink

    (University of Groningen, University Medical Center Groningen
    AstraZeneca)

  • Sharon Wolters

    (University of Groningen, University Medical Center Groningen
    Asc Academics B.V)

  • Guiling Zhou

    (University of Groningen)

  • Arjan Postma

    (Asc Academics B.V)

  • Cornelis Boersma

    (University of Groningen, University Medical Center Groningen
    Health-Ecore B.V
    Open University)

  • Job Frank Martien Boven

    (University of Groningen, University Medical Center, Groningen Research Institute for Asthma and COPD (GRIAC))

  • Maarten Jacobus Postma

    (University of Groningen, University Medical Center Groningen
    University of Groningen
    Universitas Padjadjaran)

Abstract

Objectives The aim of this study is to analyse the trends in technology appraisals for non-small cell lung cancer (NSCLC) treatments performed by the National Institute for Health and Care Excellence (NICE) over the last ten years. Methods A systematic search was conducted for single technology appraisals of NSCLC drugs in the online NICE database from 2012 to 2022. Search terms used were ‘non small cell lung cancer’, and ‘NSCLC’. Appraisals that were under development or terminated as well as multiple technology appraisals were considered out of scope. Results In the 30 included appraisals for targeted therapies and immunotherapies within NSCLC, a total of 53 different comparators were included by NICE for 41 assorted indications or subgroups. Partitioned survival models were most frequently used, often including three health states and time horizons of up to 30 years. Throughout the decade the use of indirect comparisons was high and became more established and complex over time. Of all appraisals, 90% positively recommended the treatment for use in the UK. Conclusion Technology appraisals became more complex over time due to the emergence of targeted therapies and immunotherapies, leading to multiple different indications, subpopulations and comparators that needed to be included in appraisals. Partitioned Survival Analysis (PartSA) models became the cornerstone within NSCLC, with time horizons up to 30 years and over time methods for indirect treatment comparisons became more established. The majority of the appraisals resulted in a positive recommendation for reimbursement.

Suggested Citation

  • Lotte Westerink & Sharon Wolters & Guiling Zhou & Arjan Postma & Cornelis Boersma & Job Frank Martien Boven & Maarten Jacobus Postma, 2025. "Trends in NICE technology appraisals of non-small cell lung cancer drugs over the last decade," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 26(3), pages 455-471, April.
    • Handle: RePEc:spr:eujhec:v:26:y:2025:i:3:d:10.1007_s10198-024-01711-0
    DOI: 10.1007/s10198-024-01711-0
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s10198-024-01711-0
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s10198-024-01711-0?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Helen Bell Gorrod & Ben Kearns & John Stevens & Praveen Thokala & Alexander Labeit & Nicholas Latimer & David Tyas & Ahmed Sowdani, 2019. "A Review of Survival Analysis Methods Used in NICE Technology Appraisals of Cancer Treatments: Consistency, Limitations, and Areas for Improvement," Medical Decision Making, , vol. 39(8), pages 899-909, November.
    2. Anne Jäkel & Melanie Plested & Kuntal Dharamshi & Rakhee Modha & Sarah Bridge & Adam Johns, 2013. "A Systematic Review of Economic Evaluations in Second and Later Lines of Therapy for the Treatment of Non-Small Cell Lung Cancer," Applied Health Economics and Health Policy, Springer, vol. 11(1), pages 27-43, February.
    3. Cuc Thi Thu Nguyen & Fabio Petrelli & Stefania Scuri & Binh Thanh Nguyen & Iolanda Grappasonni, 2019. "A systematic review of pharmacoeconomic evaluations of erlotinib in the first-line treatment of advanced non-small cell lung cancer," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(5), pages 763-777, July.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Elamin H. Elbasha & Jagpreet Chhatwal, 2016. "Theoretical Foundations and Practical Applications of Within-Cycle Correction Methods," Medical Decision Making, , vol. 36(1), pages 115-131, January.
    2. Daniel Gallacher & Peter Kimani & Nigel Stallard, 2022. "Biased Survival Predictions When Appraising Health Technologies in Heterogeneous Populations," PharmacoEconomics, Springer, vol. 40(1), pages 109-120, January.
    3. Zhaojing Che & Nathan Green & Gianluca Baio, 2023. "Blended Survival Curves: A New Approach to Extrapolation for Time-to-Event Outcomes from Clinical Trials in Health Technology Assessment," Medical Decision Making, , vol. 43(3), pages 299-310, April.
    4. Nicholas R. Latimer & Mark J. Rutherford, 2024. "Mixture and Non-mixture Cure Models for Health Technology Assessment: What You Need to Know," PharmacoEconomics, Springer, vol. 42(10), pages 1073-1090, October.
    5. Cuc Thi Thu Nguyen & Fabio Petrelli & Stefania Scuri & Binh Thanh Nguyen & Iolanda Grappasonni, 2019. "A systematic review of pharmacoeconomic evaluations of erlotinib in the first-line treatment of advanced non-small cell lung cancer," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(5), pages 763-777, July.
    6. Nicholas R. Latimer & Kurt Taylor & Anthony J. Hatswell & Sophia Ho & Gabriel Okorogheye & Clara Chen & Inkyu Kim & John Borrill & David Bertwistle, 2024. "An Evaluation of an Algorithm for the Selection of Flexible Survival Models for Cancer Immunotherapies: Pass or Fail?," PharmacoEconomics, Springer, vol. 42(12), pages 1395-1412, December.
    7. Ash Bullement & Matthew D. Stevenson & Gianluca Baio & Gemma E. Shields & Nicholas R. Latimer, 2023. "A Systematic Review of Methods to Incorporate External Evidence into Trial-Based Survival Extrapolations for Health Technology Assessment," Medical Decision Making, , vol. 43(5), pages 610-620, July.
    8. Daniel Gallacher & Peter Kimani & Nigel Stallard, 2021. "Extrapolating Parametric Survival Models in Health Technology Assessment: A Simulation Study," Medical Decision Making, , vol. 41(1), pages 37-50, January.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:26:y:2025:i:3:d:10.1007_s10198-024-01711-0. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.